In a double blinded, placebo-controlled trial, patients showed an average weight loss of 9.9% at 24 weeks on weekly pemvidutide (2.4mg) over placebo
Marketed under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight loss), this GLP-1 receptor agonist has redefined the landscape of chronic weight management
The term may be encompassed within the broader categories of dyspepsia, belching, and gastrointestinal discomfort that are recognised adverse reactions
Their lab markers such as insulin, CRP, triglycerides, told a story of rising inflammation
At Klinic, we work diligently to optimize your insurance benefits, manage prior authorization and connect you with savings programs, ensuring cost is not a barrier
Ustekinumab, an IL-12/IL-23 inhibitor, has shown promising results, providing effective and sustained responses in PsA patients [2, 19]